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Abstract: Bevacizumab is known to reduce Vascular Endothelial Growth Factor 
(VEGF) to undetectable levels when used in conjunction with chemotherapy. 
Hypertension is a frequent adverse effect of bevacizumab, although its mechanism(s) 
remain unclear. In this study, our aim was to examine the pathogenesis of 
bevacizumab-induced hypertension and to investigate the treatment efficacy of 
valsartan. A total of 24 Wistar Albino female rats were included in the study. Rats 
were divided into three groups with 8 rats in each, as follows: The control group, 
bevacizumab group and bevacizumab + valsartan group. Blood pressure, blood urea 
nitrogen and serum creatinine levels were measured, urine samples were collected 
for 24 hours statistical analyses were performed using IBM SPSS 20 software pack. 
Nephrectomy specimens in bevacizumab and bevacizumab + valsartan groups 
exhibited varying degrees of renal injury. Although valsartan was able to reduce the 
bevacizumab-induced rise in blood pressure, it could not prevent the development of 
nephropathy. Conclusions these findings suggest that hypertension occurring 
secondary to bevacizumab treatment in rats may be associated with mechanisms 
involving renal injury. 
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INTRODUCTION 
Since vascular endothelial growth factor (VEGF) mediated tumor angiogenesis 
plays a significant role in tumor growth, dissemination and metastasis, anti-VEGF 
treatment have become the main focus in cancer treatment (Folkman, 2002; Hicklin & 
Ellis, 2005). Bevacizumab, a recombinant human Vascular Endothelial Growth 
Factor-A monoclonal antibody (anti-VEGF-A) is known to reduce serum VEGF to 
undetectable levels while inhibiting the growth of several tumors (Hurwitz et al., 
2004).  
Hypertension is a common undesired side effect of bevacizumab therapy, and 
many theories have been put forward to explain hypertension associated with VEGF 
inhibitor treatment (Figure 1) (Touyz, Lang, Herrmann, van den Meiracker, & Danser, 
2017). These include the nitric oxide theory, peripheral vascular resistance theory, 
renal failure theory, and pre-eclampsia theory (Syrigos, Karapanagiotou, Boura, 
Manegold, & Harrington, 2011). In another study, it was concluded that genetic 
variation in WNK1, KLKB1, and GRK4 might be associated with Bevacizumab 
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induced hypertension (Frey et al., 2017). Administration of anti-VEGFR2 Semaxanib  
(SU5416) in rats resulted in renal histological abnormalities and increased arterial 
pressure (Gu et al., 2009). Inhibition of VEGF-mediated vasodilation is the dominant 
hypothesis for the pathophysiology of bevacizumab-induced hypertension (Li & 
Kroetz, 2018). Previously; bevacizumab-associated hypertension model not studied 
on rats.  
In this study, we aimed to examine the pathogenesis of bevacizumab-induced 
hypertension and to investigate the treatment efficacy of valsartan. 
 
Figure 1: Theories about VEGF-VEGFR inhibition Induced Hypertension. These 
processes result in reduced VEGFR signaling and consequent reduction in the 
production of vasodilators (NO and PGI2), increased production of vasoconstrictors 
(ET-1), oxidative stress and rarefaction, resulting in increased vascular tone and 
arterial remodeling. Reduced pressure natriuresis and impaired lymphatic function 
contribute to volume overload. p, phosphorylation site of tyrosine kinase; ROS, 
reactive oxygen species; NO, nitric oxide; ET-1, endothelin-1; Ab, antibody; ECF, 
extracellular fluid; CVD, cardiovascular disease, PGI2, prostaglandin I2. (Modified 
from Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent 
Advances in Hypertension and Cardiovascular toxicities with VEGF Inhibition. 
Hypertension. 2017; 70:220-226). 
 
MATERIALS AND METHODS 
A total of 24 female Wistar Albino rats aged between 2 and three months and 
weighing 200 g included in the study. All rats belonged to the same generation, and 
were maintained and fed under room temperature conditions (22℃). Animal 
experimentation performed by the national guidelines for use and care of laboratory 
animals, and the study protocol was approved by the Local Ethics Committee for 
Experimental Animals, Uludağ University.  
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Experimental Groups 
Group 1 (n=8): Control group. The rats in this group received physiological 
saline intraperitoneally at a dose of 10 ml/kg/week. Group 2 (n=8): The rats in this 
group received bevacizumab intraperitoneally at a dose of 10 mg/kg/week. Group 3 
(n=8): The rats in this group received oral valsartan via the drinking water at a dose 
of 10 mg/kg/day plus 10 mg/kg/week bevacizumab intraperitoneally.  
 
Experimental Protocol 
Blood pressure measurements performed at ten weeks of study in all 
experimental animals. After the study, intracardiac blood samples obtained, and 
nephrectomy specimens assessed by a single pathologist.  
 
Blood Pressure Measurements 
Blood Pressure (BPs) values were determined using the indirect tail-cuff 
method (MAY BPHR 9610-PC Tail-Cuff Indirect BP Recorder; Comment Ltd., 
Ankara, Turkey). Each cage contained only one rat. Measurements were performed 
in a quiet and calm laboratory environment and recorded digitally 
 
Biochemistry index assay 
Blood urea nitrogen and serum creatinine levels were measured using picric 
acid creatinine reagent. 
 
Urine collection  
Urine samples collected for 24 hours, from 8.00 am to 8.00 pm next day at 
Week 0 (before injection), 3, 6, 9, and 12. Measurements were performed using 
turbidimetric methods (Cobas Integra 800). 
 
Surgical Preparation  
Rats sedated with ketalar + rompun at the end of the 12th week. A midline 
incision made, and blood samples obtained from the left ventricle. Both kidneys of 
each rat were totally excised. 
 
Pathological Assessments 
Tissue samples for pathological assessments fixed for 24 h in formaldehyde 
solution with 10% neutral buffer. After routine tissue processing, four micron-thick 
cross-sections prepared from paraffin blocks stained with hematoxylin and eosin. 
Samples were histologically graded under light microscopic examination, using the 
methodology described by Bayar et al. (Bayar MK, 1998). As follows: 0, no 
pathology; 1, mild injury consisting of glomerular mesangial proliferation, interstitial 
vascular congestion; 2, moderate damage with thickening of the basal membrane, 
accumulation of substance in the tubules, interstitial nephritis; 3, severe injury with 




Statistical analyses performed at the Department of Biostatistics, Uludağ 
University using IBM SPSS 20 software pack. The normal distribution of the data 
tested with the Shapiro Wilk test. For continuous variables, median (minimum-
maximum) values were provided as descriptive statistics. In all three groups (control 
group, bevacizumab group, and bevacizumab + valsartan group) analyses were 
Medical Laboratory Technology Journal 19 
 
Copyright © 2019, MLTJ, ISSN 2461-0879 
 
performed for blood pressure values at ten weeks, blood sample results after the 
experiment, and pathological assessments. The significance of the differences 
between the three groups examined with the Kruskal Wallis test. If a significant 
difference found, pairwise comparisons using the Mann-Whitney U test performed. 
For each group, the correlations between pathological grade and blood pressure 
were investigated using Spearmen’s correlation test, where a correlation coefficient 
of 0.2-0.4, 0.4-0.7, and > 0.7 considered as mild, moderate, and strong correlation, 
respectively — the significance set at an alpha level of < 0.05.  
 
RESULTS AND DISCUSSION 
Mean systolic and diastolic blood pressures were higher in bevacizumab 
group as compared to control (p > 0.05) and bevacizumab + valsartan groups 
(p=0.08). On the other hand, mean systolic and diastolic blood pressure values were 
lower in bevacizumab + valsartan group than in bevacizumab (p > 0.05) and control 
(p > 0.05) groups (p > 0.05). Table 1 shows a more detailed summary of blood 
pressure measurements.  
 
 
Table 1. Blood pressure measurements. 
 Control Bevacizumab Bevacizumab+Valsartan 
Systolic BP 130.4 (108.6-
165.7) 
146.1 (89-242.7) 110 (91.6-143.6) 
Diastolic 
BP 
94.3 (70.6-113.4) 110.7 (63.5-
197.8) 
81.7 (39.9-105.4) 
BP: blood pressure 
 
Biochemical tests 
Kidney function tests and electrolyte levels were comparable across all three study 
groups (Table 2).  
Table 2. Results of biochemical analyses 
 Control Bevacizumab Bevacizumab+ 
Valsartan 
Urea, mg/dL 48.25 (35.8-65.1) 47.75 (36.8-58.2) 45.4 (38.5-48.4) 
Creatinine, mg/dL 0.34 (0.31-0.82) 0.28 (0.23-0.33) 0.31 (0.26-0.41) 






Potassium, mEq/L 5.7 (4.5-8.3) 5.3 (4.3-7.4) 5.5 (4.6-13.3) 
Calcium, mg/dL 10.6 (6.1-11.5) 10.9 (9.9-11.4) 11.2 (9.8-13.1) 
 
24-hour Proteinuria (mg/dL) 
In all groups, 24-hour urinary protein analyses were standard, with no 
significant differences between the study groups at 0, 3, 6, 9, and 12 weeks (Figure 
2). A moderate, but statistically insignificant positive correlation between the 
histological grade and proteinuria noted in the bevacizumab group (rs=0.682, 
p=0.063). 
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Figure 2: 24-hour urinary protein measurements in study groups 
 
Histopathological findings 
Histopathological grades were similar in bevacizumab and bevacizumab + 
valsartan groups (median 2, range 1-3 for both groups). Histological grade was 0 in 
all the rats in the control group, while it was significantly higher in bevacizumab and 
bevacizumab + valsartan groups compared to controls (p<0.001 for both 
comparisons). Grade-0, grade-1, grade-2, grade-3 nephropathy samples shown in 
Figure 3. 
 
A: Normal view Grade: 0, H & E 10X magnification. 
 
B:  Grade: 1, Glomerular hypercellularity (stars), H & E 20X magnification 
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C:   Grade: 2, hyaline cylinders (arrows), H & E 40X magnification 
 
D: Grade: 3, increased glomerular mesangium (arrows), H & E 10X magnification 
Figure 3. Examples for histological grades. 
 
In this study, rats in the bevacizumab group had higher mean blood pressure 
values as compared to other groups, while bevacizumab + valsartan group had lower 
mean blood pressure as compared to controls. Assessment of 24-hour protein 
showed no difference between the groups. In the bevacizumab group, the 
histopathological grade at 12 weeks showed a moderately positive, statistically 
insignificant association with proteinuria.  
Recent studies show an increased incidence of hypertension and proteinuria 
in patients receiving anti-VEGF antibody agents. In a systematic review and 
comprehensive meta-analysis of 72 published studies, the prevalence of 
hypertension and proteinuria in patients receiving bevacizumab were 25.3% (95% CI: 
21.5%-29.5%) and 18% (95% CI: 11.5%-26.6%), respectively (Zhao, Wang, Xu, Xu, 
& Liu, 2017). In another study, renal disease induced by anti-VEGF infusion was 
characterized by nephrotic proteinuria, endotheliosis, glomerulosclerosis, and hyaline 
deposition, as shown by renal biopsy examinations (Izzedine, Rixe, Billemont, 
Baumelou, & Deray, 2007). In this regard, it is interesting to note that pregnancies 
complicated by preeclampsia are associated with elevated soluble VEGF receptor 
one protein (sFlt-1), endothelial cell dysfunction, and proteinuria.  Such observations 
suggest that neutralization of physiologic levels of VEGF, a critical endothelial 
survival factor, may lead to proteinuria  (Sugimoto et al., 2003). The reduction of 
VEGFA production by the podocytes leads to loss of glomerular cells, resulting in 
mesangiolysis. Bevacizumab-associated proteinuria may partly be a consequence of 
increased intraglomerular pressure caused by hypertension. Despite an association 
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between hypertension and proteinuria, it is a challenging task to determine whether 
proteinuria caused by hypertension or hypertension is secondary to renal damage. It 
is also possible that both hypertension and proteinuria independently generated by 
VEGF blockage. 
Some studies have reported biopsy findings associated with bevacizumab 
induced renal damage. For instance, one patient in the low-dose arm of the trial by 
Johnson et al. (Johnson et al., 2004) developed clinically apparent nephrotic 
syndrome. This patient’s biopsy showed the presence of cryoglobulinemic 
glomerulonephritis. In the study by Miller et al., (Miller et al., 2005) in one patient 
developing nephrotic syndrome, renal biopsy showed collapsing glomerulopathy. 
Also, the results of the histopathological examination reported in a patient who 
developed new-onset hypertension and nephrotic syndrome in association with 
bevacizumab treatment for metastatic pancreatic cancer. This biopsy showed 
immune-complex–mediated focal proliferative glomerulonephritis. Nephrotic 
syndrome and hypertension resolved after discontinuation of bevacizumab  (George, 
Zhou, & Toto, 2007).  
In our study, histopathological examination of the nephrectomy specimens 
showed varying degrees of glomerular mesangial proliferation, interstitial vascular 
congestion, thickening of the basal membrane, accumulation of substance in the 
tubules, interstitial nephritis, fatty degeneration of the cellular structures, and 
permanent changes in the basal layer in rats treated with bevacizumab or 
bevacizumab + valsartan. A significant difference in histological grade found between 
control rats and the rats in the other two groups. Despite lower BP measurements in 
the bevacizumab + valsartan group, the degree of the kidney injury was similar 
between bevacizumab + valsartan and bevacizumab groups.  
Limitations of our study include a lack of NO, VEGF, and sFlt-1 as well as 
basal blood pressure measurements.  
 
CONCLUSION 
Our results suggest that hypertension occurring secondary to bevacizumab 
treatment in rats may be associated with mechanisms involving renal injury. Studies 
involving simultaneous measurements of nitric oxide, VEGF, and sFlt-1 may provide 




Bayar MK, Ö. E., Özercan İ, Erhan ÖL. (1998). Tavşanlarda tekrarlanan dozlarda 
kullanılan sevofluranın oluşturduğu renal histopatolojik değişiklikler ve plazma 
florür düzeyine etkileri. Anestezi Dergisi, 6, 144.  
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin 
Oncol, 29(6 Suppl 16), 15-18. doi:10.1053/sonc.2002.37263 
Frey, M. K., Dao, F., Olvera, N., Konner, J. A., Dickler, M. N., & Levine, D. A. (2017). 
Genetic predisposition to bevacizumab-induced hypertension. Gynecol Oncol, 
147(3), 621-625. doi:10.1016/j.ygyno.2017.09.017 
George, B. A., Zhou, X. J., & Toto, R. (2007). Nephrotic syndrome after 
bevacizumab: case report and literature review. Am J Kidney Dis, 49(2), e23-
29. doi:10.1053/j.ajkd.2006.11.024 
Gu, J. W., Manning, R. D., Jr., Young, E., Shparago, M., Sartin, B., & Bailey, A. P. 
(2009). Vascular endothelial growth factor receptor inhibitor enhances dietary 
Medical Laboratory Technology Journal 23 
 
Copyright © 2019, MLTJ, ISSN 2461-0879 
 
salt-induced hypertension in Sprague-Dawley rats. Am J Physiol Regul Integr 
Comp Physiol, 297(1), R142-148. doi:10.1152/ajpregu.90972.2008 
Hicklin, D. J., & Ellis, L. M. (2005). Role of the vascular endothelial growth factor 
pathway in tumor growth and angiogenesis. J Clin Oncol, 23(5), 1011-1027. 
doi:10.1200/JCO.2005.06.081 
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., 
. . . Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic colorectal cancer. N Engl J Med, 350(23), 2335-
2342. doi:10.1056/NEJMoa032691 
Izzedine, H., Rixe, O., Billemont, B., Baumelou, A., & Deray, G. (2007). Angiogenesis 
inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney 
Dis, 50(2), 203-218. doi:10.1053/j.ajkd.2007.04.025 
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., 
Jablons, D. M., . . . Kabbinavar, F. (2004). Randomized phase II trial 
comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and 
paclitaxel alone in previously untreated locally advanced or metastatic non-
small-cell lung cancer. J Clin Oncol, 22(11), 2184-2191. 
doi:10.1200/JCO.2004.11.022 
Li, M., & Kroetz, D. L. (2018). Bevacizumab-induced hypertension: Clinical 
presentation and molecular understanding. Pharmacol Ther, 182, 152-160. 
doi:10.1016/j.pharmthera.2017.08.012 
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., 
Fehrenbacher, L., . . . Rugo, H. S. (2005). Randomized phase III trial of 
capecitabine compared with bevacizumab plus capecitabine in patients with 
previously treated metastatic breast cancer. J Clin Oncol, 23(4), 792-799. 
doi:10.1200/JCO.2005.05.098 
Sugimoto, H., Hamano, Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar, A., & 
Kalluri, R. (2003). Neutralization of circulating vascular endothelial growth 
factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) 
induces proteinuria. J Biol Chem, 278(15), 12605-12608. 
doi:10.1074/jbc.C300012200 
Syrigos, K. N., Karapanagiotou, E., Boura, P., Manegold, C., & Harrington, K. (2011). 
Bevacizumab-induced hypertension: pathogenesis and management. 
BioDrugs, 25(3), 159-169. doi:10.2165/11590180-000000000-00000 
Touyz, R. M., Lang, N. N., Herrmann, J., van den Meiracker, A. H., & Danser, A. H. J. 
(2017). Recent Advances in Hypertension and Cardiovascular Toxicities With 
Vascular Endothelial Growth Factor Inhibition. Hypertension, 70(2), 220-226. 
doi:10.1161/HYPERTENSIONAHA.117.08856 
Zhao, T., Wang, X., Xu, T., Xu, X., & Liu, Z. (2017). Bevacizumab significantly 
increases the risks of hypertension and proteinuria in cancer patients: A 
systematic review and comprehensive meta-analysis. Oncotarget, 8(31), 
51492-51506. doi:10.18632/oncotarget.18190 
 
